Literature DB >> 3863757

Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeruginosa.

D O Sordelli, M C Cerquetti, G el-Tawil, P W Ramwell, A M Hooke, J A Bellanti.   

Abstract

In chronic P. aeruginosa infection, lung tissue damage is induced by either the microorganism or the inflammatory response. We investigated, in an animal model, whether a non-steroidal anti-inflammatory drug, ibuprofen, reduced lung inflammation produced by P. aeruginosa. Lung lavages, pulmonary clearance of P. aeruginosa and lung pathology were studied in CD-1 mice injected with sodium ibuprofenate. A single dose of the drug, injected immediately after 30 min exposure to the P. aeruginosa aerosol, decreased the recruitment of granulocytes into airways in a dose-dependent manner. Pretreatment with 2 doses of the drug 18 and 6 h before the P. aeruginosa challenge was even more effective. The kinetics of changes in prostaglandin E2, 6-keto-prostaglandin F1 alpha and thromboxane B2 concentrations in lung lavage fluids after P. aeruginosa aerosol were also modified by ibuprofen. Moreover, ibuprofen treatment did not impair lung clearance of the challenge microorganisms, and the animals had less inflammation of the lungs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3863757

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  11 in total

1.  Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion.

Authors:  D C Devor; B D Schultz
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

2.  In vitro antibacterial activity of Ibuprofen and acetaminophen.

Authors:  Ali Abdul Hussein S Al-Janabi
Journal:  J Glob Infect Dis       Date:  2010-05

3.  Piroxicam-copper complexes: inhibition of polymorphonuclear leukocyte migration to Pseudomonas aeruginosa chemotactins in vivo and superoxide dismutase-like activity in vitro.

Authors:  D O Sordelli; P A Fontán; C R Amura
Journal:  Agents Actions       Date:  1993-03

Review 4.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

5.  Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice.

Authors:  C Morissette; E Skamene; F Gervais
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

6.  The effect of a cyclooxygenase inhibitor on the in vivo polymorphonuclear leukocyte migration to Pseudomonas aeruginosa peptide chemotactins.

Authors:  P A Fontán; C R Amura; D O Sordelli
Journal:  Agents Actions       Date:  1993-09

7.  E-prostanoid 2 receptor signaling suppresses lung innate immunity against Streptococcus pneumoniae.

Authors:  David M Aronoff; Ingrid L Bergin; Casey Lewis; Deepti Goel; Edmund O'Brien; Marc Peters-Golden; Peter Mancuso
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-04-02       Impact factor: 3.072

8.  Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens.

Authors:  Parth N Shah; Kimberly R Marshall-Batty; Justin A Smolen; Jasur A Tagaev; Qingquan Chen; Christopher A Rodesney; Henry H Le; Vernita D Gordon; David E Greenberg; Carolyn L Cannon
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 9.  State of progress in treating cystic fibrosis respiratory disease.

Authors:  Patrick A Flume; Donald R Van Devanter
Journal:  BMC Med       Date:  2012-08-10       Impact factor: 8.775

10.  Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution.

Authors:  Néstor H García; Daniela J Porta; Roxana V Alasino; Sonia E Muñoz; Dante M Beltramo
Journal:  Med Hypotheses       Date:  2020-07-07       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.